Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Laboratory of Translational Nutrition Biology, Federal Institute of Technology Zurich ETHZ, Zurich, Switzerland.
Adv Exp Med Biol. 2018;1065:379-388. doi: 10.1007/978-3-319-77932-4_24.
Orthotopic heart transplantation (OHT) is the "gold standard" treatment for patients with end-stage heart failure, with approximately 5000 transplants performed each year worldwide. Heart transplantation survival rates have progressively improved at all time points, despite an increase in donor and recipient age and comorbidity and greater recipient urgency; according to the registry of the International Society of Heart and Lung Transplantation (ISHLT), the median survival of patients posttransplantation is currently 12.2 years.Long-term survival is sub-optimal, and outcomes after OHT remain constrained by the development of acute rejection and cardiac allograft vasculopathy (CAV). Moreover, donor organs are in short supply, making optimal organ utilization an ongoing priority. For these reasons, substantial interest continues to exist in identifying factors portending increased survival and improved organ utilization.
原位心脏移植（OHT）是终末期心力衰竭患者的“金标准”治疗方法，全世界每年大约进行 5000 例移植手术。尽管供体和受体年龄增加、合并症更多以及受体的紧迫性增加，但心脏移植的存活率在各个时间点都在逐步提高；根据国际心肺移植协会（ISHLT）的登记处，目前患者移植后的中位生存期为 12.2 年。长期生存情况并不理想，OHT 的结果仍然受到急性排斥和心脏移植物血管病（CAV）的发展的限制。此外，供体器官短缺，因此最佳的器官利用仍然是一个持续的优先事项。由于这些原因，人们仍然非常关注识别预示着更高存活率和更好的器官利用率的因素。
